Potential suitor for CHM is BioNTech. They have USD21bn in the bank and have stated they want to build an oncology pipeline. Augurs well for leading cell therapy companies such as CHM l!
CHM Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.